We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+10.61%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$1.92B
AUM Growth
+$154M
Cap. Flow
+$62.7M
Cap. Flow %
3.27%
Top 10 Hldgs %
26.22%
Holding
151
New
15
Increased
40
Reduced
15
Closed
11

Top Buys

Rank Stock Value
1
JELD icon
JELD-WEN Holding
JELD
+$18.8M
2
LII icon
Lennox International
LII
+$14.6M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$8.18M
4
TTD icon
Trade Desk
TTD
+$8.01M
5
VRNS icon
Varonis Systems
VRNS
+$7.91M

Top Sells

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$21.1M
2
CYBR
CyberArk
CYBR
+$14M
3
ABBV icon
AbbVie
ABBV
+$10.1M
4
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$9.2M
5
XPO icon
XPO
XPO
+$7.1M

Sector Composition

Rank Sector Weight
1 Healthcare 36.8%
2 Consumer Discretionary 13.92%
3 Technology 13.08%
4 Industrials 10.12%
5 Utilities 4.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VCYT icon
51
Veracyte
VCYT
$4.77B
$13.9M 0.73%
2,133,500
– –
TWLO icon
52
Twilio
TWLO
$29B
$13.6M 0.71%
575,000
+118,000
+26% +$3.31M
APTV icon
53
Aptiv
APTV
$12.3B
$13.4M 0.7%
158,000
– –
PANW icon
54
Palo Alto Networks
PANW
$265B
$13M 0.68%
540,000
+123,768
+30% +$3.01M
DOOR
55
DELISTED
MASONITE INTERNATIONAL CORP
DOOR
$12.6M 0.66%
170,000
-55,000
-24% -$3.84M
AGIO icon
56
Agios Pharmaceuticals
AGIO
$1.95B
$12.2M 0.64%
214,000
– –
NBIX icon
57
Neurocrine Biosciences
NBIX
$18.7B
$12.1M 0.63%
156,000
+31,000
+25% +$2.11M
VYGR icon
58
Voyager Therapeutics
VYGR
$189M
$11.7M 0.61%
703,425
+142,000
+25% +$2.43M
ALNY icon
59
Alnylam Pharmaceuticals
ALNY
$27.4B
$11.4M 0.6%
90,000
– –
BPMC
60
DELISTED
Blueprint Medicines
BPMC
$11.3M 0.59%
150,000
-86,000
-36% -$6.05M
ACAD icon
61
Acadia Pharmaceuticals
ACAD
$4.55B
$10.1M 0.53%
334,700
– –
TSLA icon
62
Tesla
TSLA
$1.22T
$9.34M 0.49%
450,000
– –
SRPT icon
63
Sarepta Therapeutics
SRPT
$1.64B
$8.96M 0.47%
161,000
– –
GWPH
64
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$8.38M 0.44%
63,500
– –
VIRX
65
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$8.36M 0.44%
64,727
+64,353
+17,207% +$6.03M
VRNS icon
66
Varonis Systems
VRNS
$4.58B
$8.16M 0.43%
+504,000
New +$7.91M
VBIV
67
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$7.9M 0.41%
+61,667
New +$7.58M
FENC icon
68
Fennec Pharmaceuticals
FENC
$344M
$7.39M 0.39%
+741,175
New +$7.4M
CERN
69
DELISTED
Cerner Corp
CERN
$7.29M 0.38%
108,200
– –
AKCA
70
DELISTED
Akcea Therapeutics Inc
AKCA
$7.29M 0.38%
420,000
– –
EXR icon
71
Extra Space Storage
EXR
$31.3B
$7.17M 0.37%
82,000
– –
BOLD
72
DELISTED
Audentes Therapeutics, Inc
BOLD
$7.03M 0.37%
225,000
– –
MYOV
73
DELISTED
Myovant Sciences Ltd.
MYOV
$6.98M 0.36%
552,100
+2,100
+0.4% +$28.2K
KALV
74
DELISTED
KalVista Pharmaceuticals
KALV
$6.91M 0.36%
709,000
+313,000
+79% +$3.26M
FPRX
75
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$6.91M 0.36%
315,000
-286,000
-48% -$9.2M
1 2
3
4 5

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q4 2017 Portfolio in Review

As of Q4 2017, Eventide Asset Management held 151 positions worth $1.92B, up 8.7% from $1.76B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Eventide Asset Management deployed $62.7M of net new capital in Q4 2017, opening 15 new positions and adding to 40 existing holdings. Its largest new stake was JELD-WEN Holding: 506,500 shares worth $19.9M.

By sector, the portfolio is most concentrated in Healthcare at 37% of assets, down from 38% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was bluebird bio, an estimated $21.1M trimmed.

  • Eventide Asset Management's largest Q4 2017 buy was JELD-WEN Holding: 506,500 shares worth $19.9M.
  • Eventide Asset Management added most to AveXis, Inc. Common Stock in Q4 2017, an estimated $8.18M increase.
  • Eventide Asset Management's biggest Q4 2017 reduction was bluebird bio, cutting an estimated $21.1M.
  • Eventide Asset Management fully exited CyberArk in Q4 2017, selling an estimated $14M.
  • Eventide Asset Management's ten largest holdings make up 26% of its $1.92B portfolio in Q4 2017.
  • Eventide Asset Management opened 15 new positions and closed 11 in Q4 2017.
  • Eventide Asset Management's portfolio value rose 8.7% quarter-over-quarter to $1.92B.

Based on Eventide Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.